Skip to main content
. Author manuscript; available in PMC: 2011 Oct 1.
Published in final edited form as: Int Immunopharmacol. 2010 Jul 15;10(10):1220–1228. doi: 10.1016/j.intimp.2010.07.002

Figure 5. Sorafenib partially inhibits AKT activation and GSK3β phosphorylation.

Figure 5

(A.) BMMΦ pretreated with vehicle or Sorafenib (5µM) were stimulated with LPS+PGE for 15’, 30’, 45’, or 60’. Lysates were assayed for pAKT (Ser473), p-GSK3α/β (Ser21/9), and total AKT by western blotting. (B.) Image quantitation of AKT and GSK3β phosphorylation from (A.) (C.) BMMΦ were stimulated for LPS or LPS+PGE for 15’, 30’, 45’, 60’. Western blotting was performed as in (A.). Figures are representative of at least two independent experiments.